Six whistleblowers scored a major victory Thursday when the global consumer goods conglomerate Reckitt Benckiser Group announced a record $1.4 billion civil settlement with the federal government over sales and marketing of the opioid Suboxone.

The U.S. Department of Justice said the RB Group also entered a nonprosecution agreement to resolve potential criminal charges. The settlement included the U.K.-based group and its subsidiary in New Jersey, Reckitt Benckiser LLC.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]